American Biogenetic Sciences Inc., of Copiague, N.Y., appointed Alfred Roach CEO and Josef Schoell president and chief operating officer. Schoell also will serve on the board.
Cytogen Corp., of Princeton, N.J., appointed Kevin Lokay to its board.
DoubleTwist Inc., of Oakland, Calif., said Robert Williamson is now president and chief operating officer, and Edward Kiruluta is now chief technology officer.
Endorex Corp., of Chicago, named Panayiotis Constantinides vice president, research and development.
Exelixis Inc., of South San Francisco, added Peter Lamb as senior director of molecular pharmacology and structural biology, Kirk McMillan as director of new lead discovery, John Nuss as senior director of chemistry, and Yifan Zhai as director of pharmacology.
Forbes Medi-Tech Inc., of Vancouver, British Columbia, elected Donald Buxton and Joe Dunne to its board.
Gemini Genomics plc, of Cambridge, UK, added M.C. Sullivan as executive vice president of corporate communications and bioethics.
Genometrix Inc., of The Woodlands, Texas, promoted Stafford Brignac to vice president of engineering.
Genset SA, of Paris, appointed Jeffery Vick as vice president, worldwide business development and licensing.
GenVec Inc., of Gaithersburg, Md., elected Wayne Hockmeyer to its board.
Gilead Sciences Inc., of Foster City, Calif., appointed James Denny chairman of its board.
Kinetek Pharmaceuticals Inc., of Vancouver, British Columbia, promoted Jasbinder Sanghera to chief scientific officer and Gabe Kalmar to vice president, research and development operations.
Merlin Technologies Inc., of Boston, appointed Raymond Baddour to its board.
Molecular Targeting Technology Inc., of West Chester, Pa., added Jeffrey Mattis as senior vice president of development.
Neoprobe Corp., of Dublin, Ohio, appointed Nancy Katz to its board.
Novazyme Pharmaceuticals Inc., of Oklahoma City, appointed Pedro Huertas chief medical officer and vice president of business strategy, Julie Smith as senior director of patient advocacy, Jerry Baty as controller, Elvira Ponce as director of preclinical development and Bridget Leenstra as director of planning and administration.
Novirio Pharmaceuticals Inc., of Cambridge, Mass., appointed Nathaniel Brown senior vice president, hepatitis clinical affairs.